{"entity":{"id":"nct06090266","kind":"trial","name":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","aka":[],"tldr":"A phase 1/2 trial of Cemiplimab in metastatic cancer and melanoma, run by OncoResponse, Inc., now recruiting.","summary":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents is a phase 1/2 interventional study registered as NCT06090266 by OncoResponse, Inc., with 168 participants planned, started 2023-10-24 and due to reach its primary completion in 2026-08-01. Interventions recorded: OR502, Cemiplimab. Conditions listed: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06090266","url":"https://clinicaltrials.gov/study/NCT06090266"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","melanoma","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab","or502"],"companies":["oncoresponse"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06090266","phase":"1/2","setting":"A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies","sponsor":"OncoResponse, Inc.","participation":[{"nct":"NCT06090266","source":"https://clinicaltrials.gov/study/NCT06090266","fetchedAt":"2026-10-07T16:54:11.803Z","studySha256":"f07d5c7d4c8da69a423fd92e4dbedb8934114281d73cc2f4820c206da60732eb","overallStatus":"RECRUITING","lastUpdatePosted":"2025-01-07","leadSponsor":"OncoResponse, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":168,"enrolmentType":"ESTIMATED","siteCount":4,"recruitingSiteCount":4,"countries":["United States"]}],"started":"2023-10-24","startedType":"actual","enrolled":168,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06090266/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"},{"id":"or502","kind":"drug","name":"OR502","route":"/drugs/or502/"}],"company":[{"id":"oncoresponse","kind":"company","name":"OncoResponse","route":"/companies/oncoresponse/"}]}}